- Stocks
- Pharma & Healthcare
- Lyka Labs
Lyka Labs share price
NSE: LYKALABSPharma & HealthcareBiotechnology
Lyka Labs at a glance
Lyka Labs (NSE: LYKALABS) closed at ₹86.04 on 19 Oct 2026, down 1.99% on the day. With a market capitalisation of ₹311 Cr, it ranks 2036th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was −10.9% in FY26. Over the past year the share price has fallen 9.0%. Its 52-week range is ₹44.10 (30 Mar 2026) to ₹98.90 (24 Oct 2025); the last close is 13.0% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹28 Cr (−16.2% year on year) and net profit −₹8 Cr (−497.5%), on a consolidated basis. Promoters held 58.45% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹311 CrRank 2036 on NSE
- Price to book
- 1.73×FY26
- EPS (TTM)
- −₹2.86to Q4 FY26
- ROE
- −10.9%FY26
- ROCE
- −7.0%FY26
- Debt to equity
- 0.52FY26
- Net profit margin
- −8.1%FY26
- Book value / share
- ₹25.89FY26
- 52-week high
- ₹98.9024 Oct 2025
- 52-week low
- ₹44.1030 Mar 2026
- 1-year return
- −9.0%
- RSI (14-day)
- 62.3
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.99% | +18.1% | +5.3% | +25.6% | −9.0% |
Lyka Labs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹30 Cr | ₹41 Cr | ₹34 Cr | ₹33 Cr | ₹33 Cr | ₹37 Cr | ₹31 Cr | ₹28 Cr |
| Revenue YoY | +31.6% | +47.1% | +3.8% | +20.4% | +9.7% | −10.9% | −9.1% | −16.2% |
| Net profit | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | −₹3 Cr | −₹0 Cr | −₹8 Cr |
| Net profit YoY | — | — | +34.3% | — | −22.5% | −268.1% | −105.6% | −497.5% |
| Net margin | 4.3% | 4.6% | 8.0% | 6.1% | 3.0% | −8.8% | −0.5% | −28.8% |
| EPS | ₹0.40 | ₹0.58 | ₹0.75 | ₹0.49 | ₹0.25 | −₹0.94 | −₹0.04 | −₹2.13 |
Lyka Labs financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹86 Cr | ₹194 Cr | ₹93 Cr | ₹111 Cr | ₹139 Cr | — |
| Operating profit | −₹13 Cr | ₹66 Cr | −₹6 Cr | −₹1 Cr | ₹11 Cr | — |
| Net profit | −₹10 Cr | ₹38 Cr | −₹13 Cr | −₹3 Cr | ₹8 Cr | — |
| EPS (₹) | −₹4.00 | ₹14.00 | −₹5.00 | −₹1.00 | ₹2.00 | — |
| Cash from operations | ₹9 Cr | ₹79 Cr | ₹9 Cr | ₹2 Cr | ₹2 Cr | — |
| Total debt | ₹151 Cr | ₹62 Cr | ₹63 Cr | ₹42 Cr | ₹18 Cr | ₹23 Cr |
| Shareholders' equity | −₹25 Cr | ₹14 Cr | ₹47 Cr | ₹69 Cr | ₹105 Cr | ₹92 Cr |
Lyka Labs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 58.16% | 58.16% | 58.16% | 58.16% | 58.16% | 58.45% |
| Foreign institutions | 0.23% | 0.16% | 0.18% | 0.17% | 0.29% | 0.17% |
| Domestic institutions | 0.67% | 0.67% | 0.67% | 0.67% | 0.67% | 0.66% |
| Non-institutions | 40.94% | 41.01% | 41.00% | 41.00% | 40.88% | 40.72% |
Lyka Labs vs peers
The listed Pharma & Healthcare companies nearest to Lyka Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
| AAREYDRUGSAarey Drugs & Pharmaceuticals | ₹114.47 | +1.30% | +39.6% | ₹325 Cr | 82.4 | — |
| LYKALABSLyka Labs | ₹86.04 | −1.99% | −9.0% | ₹311 Cr | — | — |
| NURECANureca | ₹317.10 | −2.40% | +37.8% | ₹303 Cr | 149.6 | — |
| AMBALALSAAmbalal Sarabhai Enterprises | ₹38.95 | +3.18% | — | ₹298 Cr | 16.8 | — |
| BIJHANSBijoy Hans | — | — | — | ₹292 Cr | — | — |
| ASTONEALABAstonea Labs | — | — | — | ₹281 Cr | — | — |
Ask anything about Lyka Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against LYKALABS's own history. Try: “Why has LYKALABS moved over the last three months?” · “Backtest a 50-day moving-average crossover on LYKALABS over five years” · “Compare LYKALABS with ASTALLTD on margins and valuation”
Frequently asked questions about Lyka Labs
What is the share price of Lyka Labs today?
Lyka Labs (NSE: LYKALABS) last closed at ₹86.04 on 19 Oct 2026. Its 52-week high is ₹98.90 and its 52-week low is ₹44.10.
What is the market cap of Lyka Labs?
Lyka Labs' market capitalisation is ₹311 Cr (₹311 Cr) at the 19 Oct 2026 close, ranking 2036th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Lyka Labs?
Return on equity was −10.9% in FY26 and return on capital employed was −7.0% in FY26 (consolidated figures).
Is Lyka Labs a debt-free company?
No. Lyka Labs' debt-to-equity ratio was 0.52 in FY26, with total debt of ₹23 Cr.
What were Lyka Labs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Lyka Labs reported revenue of ₹28 Cr, −16.2% year on year, and net profit of −₹8 Cr, −497.5% year on year.
How has Lyka Labs stock performed over the last year?
Lyka Labs' share price has fallen 9.0% over the past year, +25.6% over three months and +5.3% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Lyka Labs?
As of 30 Jun 2026: promoters 58.45%, foreign institutions 0.17%, domestic institutions 0.66%, non-institutions 40.72%.
Who are Lyka Labs' competitors?
The listed Pharma & Healthcare companies closest to Lyka Labs by market cap are Astal Lab, Aarey Drugs & Pharmaceuticals, Nureca, Ambalal Sarabhai Enterprises, Bijoy Hans and Astonea Labs.
Is Lyka Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Lyka Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LYKALABS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with L · all NSE stocks · this page as text